● Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Condition: Metastatic Hepatocellular Carcinoma · Solid Tumors · Solid Tumor, Adult · Sponsor: Tyra Biosciences, Inc

PhasePhase 1

Planned participants100

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Grace Indyk · 858-356-2323 · TyraClinicalTrials@tyra.bio

Always discuss trial participation with your own doctor first.

Locations (16)

USC Norris Comprehensive Cancer Center	Los Angeles, California, United States	Recruiting
UCSF Medical Center at Mount Zion	San Francisco, California, United States	Recruiting
Stanford Cancer Institute	Stanford, California, United States	Recruiting
The University of Kansas Medical Center	Westwood, Kansas, United States	Recruiting
John Hopkins University	Baltimore, Maryland, United States	Recruiting
Mass General Cancer Center	Boston, Massachusetts, United States	Recruiting
Karmanos Cancer Institute	Detroit, Michigan, United States	Recruiting
Columbia University Irving Medical Center	New York, New York, United States	Recruiting
Sarah Cannon Research Institute Oncology Partners	Nashville, Tennessee, United States	Recruiting
University Health Network Princess Margaret Cancer Center	Toronto, Ontario, Canada	Recruiting
Asan Medical Center	Seoul, South Korea	Recruiting
Samsung Medical Center	Seoul, South Korea	Recruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06915753